News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Bernard Escudier, MD, Institut Gustave Roussy

Articles by Bernard Escudier, MD, Institut Gustave Roussy

Final Thoughts on the Management of mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Additional Emerging Therapies for Progressive mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Emerging Agents for Progressive mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Sequencing After Frontline I/O Based Regimen for mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Clinical Trials for Relapsed/Refractory mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Upcoming Combination Trials for mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

I/O Therapy After Progression on I/O for mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Role of TKI After Progression on I/O for mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Review of the COSMIC 021 Study for mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Introduction and Review of CheckMate 9ER for Metastatic RCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Latest Updated Articles

Role of TKI After Progression on I/O for mRCC
October 23rd 2020
Emerging Agents for Progressive mRCC
October 23rd 2020
Review of the COSMIC 021 Study for mRCC
October 23rd 2020
I/O Therapy After Progression on I/O for mRCC
October 23rd 2020
Introduction and Review of CheckMate 9ER for Metastatic RCC
October 23rd 2020
$Clinical Trials for Relapsed/Refractory mRCC$
Clinical Trials for Relapsed/Refractory mRCC
October 23rd 2020

Trending on OncLive

FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC

MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma

Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis

FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC

CLL14 Final Analysis Shows Long-Term PFS Gain With Venetoclax/Obinutuzumab in Previously Untreated CLL